Single Use Imaging
+ Artificial Intelligence
= The Future of Surgery


The history of modern surgery has always involved battling infections that occur as a result of operations. Even with modern sterilization techniques, 4,000,000 patients acquire infections annually and two-thirds of them have infections that resist at least one drug. 500,000 Americans die from hospital-bred infections. Methicillin-resistant Staphylococcus aureus (MRSA) infections are “caused by a type of staph bacteria that’s become resistant to many of the antibiotics used to treat ordinary staph infections.” In 2005 “The Annual costs of treating hospitalized MRSA patients are approximately $4.2 billion in the United States. ”
Hospital Infections Annually
Deaths Annually
Preventable Infection Costs
$ 0 Billion

The FDA recommends Single Use Imaging

SterileWave Single Use Proprietary Endoscopes Combined with Artificial Intelligence (AI) creates Ultra High Resolution Images to Detect and Visualize Diseased Tissue

SterileWave™ is revolutionizing the way minimally invasive surgery is performed with intraoperative surgical imaging combined with advanced image enhancement, Raman Spectroscopy and Spectral Analysis to create Artificial Intelligence (AI) to assist the surgeon diagnosing tumors thereby, providing better outcomes for the patient and better tools for the surgeon. Advanced three-dimensional video data coupled with head mounted three-dimensional visualization has the potential to mitigate surgical errors, enhance patient outcomes, and dramatically improve cost savings to healthcare systems.


Standard SterileWave
Standard SterileWave

SterileWaves’ enhanced imaging software suite generates real-time images from endoscope video outputs and generates state-of-the-art images providing an unchallenged diagnostic tool for the physician.

SterileWave’s Raman spectroscopy using the working channels provides a real-time way of diagnosing disease.

² E. Rojas and L. Liu, “Estimating the annual hospital excess cost of methicillin-resistant Staphylococcus aureus infections in the United States,” presented at International Society for Pharmacoeconomics and Outcomes Research (IPSOR) Tenth Annual International Meeting, Washington, DC, May 2005.